Vizsgálati helyszín
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York 10021, Egyesült ÁllamokMég nincs intézményhez kötve
- 19futó vizsgálat
- 8lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 28 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 1. fázis15 vizsgálat
- 1/2. fázis5 vizsgálat
- 2. fázis4 vizsgálat
- 3. fázis3 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Toboroz12 vizsgálat
- Fut, nem toboroz6 vizsgálat
- Lezárult6 vizsgálat
- Leállították2 vizsgálat
- Még nem toboroz1 vizsgálat
- Felfüggesztve1 vizsgálat
- Fő szponzor
- Eli Lilly and Company9 vizsgálat
- C4 Therapeutics, Inc.2 vizsgálat
- Coherus Oncology, Inc.2 vizsgálat
- Daiichi Sankyo2 vizsgálat
- Aadi Bioscience, Inc.1 vizsgálat
- és még 12
Futó vizsgálatok
Még nem toboroz
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
NCT07928258· 1. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
NCT07701941· 1/2. fázis· Daiichi Sankyo· Forrás
Toboroz
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328· 1. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT07213791· 1. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601· 1. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923· 1. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
NCT06657144· 1. fázis· Coherus Oncology, Inc.· Forrás
Contact: Amin Yaqubie
Fut, nem toboroz
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
NCT06679985· 2. fázis· Coherus Oncology, Inc.· Forrás
Toboroz
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
NCT06644755· 1. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185· 1. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515· 1. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
NCT06400472· 1. fázis· Eli Lilly and Company· Forrás
Contact: Chrisann Kyi (principal investigator)
Toboroz
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626· 3. fázis· LeonaBio· Forrás
Contact: Sherry Shen
Toboroz
A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
NCT05765812· 1/2. fázis· Debiopharm International SA· Forrás
Contact: Debiopharm International S.A
Toboroz
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
NCT05826535· 1/2. fázis· Lyell Immunopharma, Inc.· Forrás
Contact: Stephen Simko, MD
Fut, nem toboroz
A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma
NCT04485949· 2. fázis· Imvax· Forrás
Toboroz
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
NCT05614739· 1. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT04180371· 1/2. fázis· BicycleTx Limited· Forrás
Toboroz
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
NCT03715933· 1. fázis· Inhibrx Biosciences, Inc· Forrás
Contact: Care Advisors
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
NCT05561751· 2. fázis· GPCR Therapeutics, Inc.· Forrás
Lezárult
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
NCT05668585· 1. fázis· C4 Therapeutics, Inc.· Forrás
Leállították
A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
NCT05269355· 2/3. fázis· PTC Therapeutics· Forrás
Leállították
A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors
NCT05355753· 1. fázis· C4 Therapeutics, Inc.· Forrás
Lezárult
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
NCT05103358· 2. fázis· Aadi Bioscience, Inc.· Forrás
Lezárult
A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia
NCT05326516· 1. fázis· Syndax Pharmaceuticals· Forrás
Lezárult
Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy
NCT04447118· 3. fázis· Jiangsu HengRui Medicine Co., Ltd.· Forrás
Lezárult
A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
NCT04083235· 3. fázis· Ipsen· Forrás
Hibát jelzek